吉西他滨(Gemcitabine) - 药物靶点：RNRs_在研适应症：胰腺癌，局部晚期胰腺腺癌，转移性胰腺导管腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

D07001-Softgel、Gemcitabine、Gemcitabine (USAN/INN)

+ [4]

靶点

RNRs

作用方式

抑制剂

作用机制

RNR抑制剂(核糖核苷酸还原酶复合体抑制剂)、DNA合成抑制剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [5]

在研适应症

胰腺癌局部晚期胰腺腺癌转移性胰腺导管腺癌+ [11]

非在研适应症

晚期胆管癌晚期癌症晚期非小细胞肺癌+ [27]

原研机构

FUJIFILM Corp.

在研机构

RenovoRx, Inc.

Merck Sharp & Dohme Corp.

Merck & Co., Inc.

+ [6]

非在研机构

Sanofi

Pfizer Inc.

Eli Lilly & Co.

+ [10]

权益机构

FUJIFILM Holdings Corp.

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)无进展

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C9H11F2N3O4

InChIKeySDUQYLNIPVEERB-QPPQHZFASA-N

CAS号95058-81-4

关联

1,167

项与吉西他滨相关的临床试验

NCT06364904

/ Not yet recruiting临床3期IIT

A Multicenter, III Stage, Randomized Controlled Trail on the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib in Untreated Unresectable and Metastatic Urothelial Carcinoma.

The aim of this study is to see whether the Trilaciclib is safe and effective in slowing down the growth of bladder cancer in patients while taking chemoimmunotherapy.

开始日期2025-10-01

申办/合作机构

中山大学孙逸仙纪念医院

NCT06622057

/ Not yet recruiting临床3期

Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens

The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS).
Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.

开始日期2025-07-01

申办/合作机构

因华生技制药股份有限公司

NCT05700448

/ Not yet recruiting临床3期

A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL)

The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.

开始日期2025-06-01

申办/合作机构

基石药业

100 项与吉西他滨相关的临床结果

登录后查看更多信息

100 项与吉西他滨相关的转化医学

登录后查看更多信息

100 项与吉西他滨相关的专利（医药）

登录后查看更多信息

29,585

项与吉西他滨相关的文献（医药）

2025-12-31·Molecular & Cellular Oncology

CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549

Article

作者: Ma, Xuan ; Liang, Ai-Ling ; Fu, Tian ; Wang, Wen-Xuan ; Ke, Zhi-Yin ; Wang, Xue-Chun ; Liu, Yong-Jun ; Yin, Hai-Han

The purpose of the study is mainly to investigate anti proliferation of non-small cell lung cancer A549 cells and its mechanism by inhibition of CHK1 expression combined with gemcitabine. The mRNA and protein levels of genes were analyzed by RT-qPCR and Western blot, respectively. Cell viability was detected by CCK-8 assay and clone formation assay. The detection of the cell cycle was used by Annexin V/7-amino-actinomycin D apoptosis detection kit. Analysis of DNA damage was done by immunofluorescence and alkaline comet assay. The results showed that inhibition of CHK1 and gemcitabine combination significantly reduced the proliferation ability of the two cell lines. We also revealed the degradation of full-length PARP and reduced Bcl-2/Bax ratio on increased apoptosis. Inhibition of CHK1 expression leads to DNA damage, induces phosphorylation of γ-H2AX, and affects the repair of homologous recombination ability through Rad51. Mechanistically, gemcitabine increased phosphorylation-ATR and phosphorylation-CHK1, indicating activation of the DNA repair system and ATR-CHK1-CDC25A pathway. Inhibition of CHK1 resulted in increased synthesis of CDK2/Cyclin A2 and CDK2/Cyclin E1 complexes, and more cells entered the subsequent cell cycle, leading to S phase arrest and mitotic catastrophe. We identified inhibition of CHK1 as a potential treatment for NSCLC and confirmed that inhibition of this kinase could overcome acquired gemcitabine resistance.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States

Article

作者: Li, Jia ; Mahmoudjafari, Zahra ; Masaquel, Anthony ; Parisé, Hélène ; Bercaw, Eric ; Bognar, Katalin ; Wang, Si-Tien

BACKGROUND:

Glofitamab is a T-cell engaging bispecific monoclonal antibody that was granted accelerated approval from the United States Food and Drug Administration for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after ≥2 lines of systemic therapy (3L+).

METHODS:

A budget impact model was developed for a hypothetical blended commercial/Medicare health plan with 1,000,000 members. Comparators were axicabtagene ciloleucel (Axi-cel), lisocabtagene maraleucel (Liso-cel), tisagenlecleucel (Tisa-cel), loncastuximab tesirine, polatuzumab vedotin + bendamustine + rituximab, rituximab + gemcitabine + oxaliplatin, tafasitamab + lenalidomide, and epcoritamab (Epcor). Total costs included those for drugs, wastage, administration, grade ≥3 adverse reactions, and all-grade cytokine release syndrome) and routine care. Market shares were based on internal projections and expert opinions. Total and per-member per-month (PMPM) net budget impacts over 3 years were calculated.

RESULTS:

Approximately nine patients were projected to be eligible for 3L + DLBCL treatment in a health plan of 1,000,000 members. The introduction of glofitamab as a treatment option resulted in estimated total and PMPM cost savings of $728,697 and -$0.0202, respectively, over 3 years. Costs were reduced across all cost categories but particularly in drug costs. Among the newer therapies, total 3-year cost per treated patient was lowest for glofitamab: $226,658 versus Tisa-cel = $564,113; Axi-cel = $540,002; Liso-cel = $516,272; and Epcor = $335,293. Across all sensitivity analyses, the inclusion of glofitamab had minimal PMPM budget impact, ranging from -$0.0256 to -$0.0108.

CONCLUSIONS:

With the lowest 3-year total cost per treated patient among the newer therapies, glofitamab being an available option in the 3L + DLBCL market is estimated to save a hypothetical 1,000,000-member health plan $728,697 in cumulative total costs and $0.0202 in PMPM costs over 3 years.

2025-12-01·Journal of Gastrointestinal Cancer

Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT)

Article

作者: Naik, Nagendra ; Priyanka, Parul ; Agrawal, Sushma

INTRODUCTION:

Retroperitoneal lymphadenopathy is considered a metastatic disease in GBC; however, some surgical series of radical surgery with enlarged RPLN who underwent RPLN dissection have shown results marginally inferior to those without enlarged RPLN. Radiological RPLN comprises a major proportion of advanced non-metastatic GBC. There is dilemma in the intent of treatment to be offered in such cases. We are reporting our series of outcome of GBC with RPLN treated with first-line CT followed by consolidation CTRT.

MATERIALS AND METHODS:

Non-metastatic locally advanced GBC with good performance status (KPS ≥ 80) were initiated on first-line CT (cisplatin-gemcitabine), and thereafter, responders were evaluated by CECT-angiography and PET-CT scan for resectability. If found unresectable, they were offered consolidation CTRT to a dose of 45 Gy by conventional fractionation (3D-CRT technique) along with concurrent capecitabine at 1250 mg/m² to GBC and regional lymphatics including RPLN. Thereafter, boost dose of 9 Gy/5# was given to GBC only. Response assessment was done using CECT abdomen by RECIST criteria v 1.1. Outcomes (overall survival) of the two groups (RPLN vs non-RPLN) were computed with Kaplan-Meier survival curves and chi-square tests using SPSS v 20.

RESULTS:

Among 189 patients of advanced non-metastatic GBC recruited from 2011 to 2022, 80 had RPLN. The demographic features of both groups were comparable. Overall, 68% of the patients were women, 30% underwent upfront stenting for obstructive jaundice, and 90% had T3 and T4 disease. Only 10% had undergone upfront laparoscopic staging and had pathologically proven RPLN. Forty percent of the patients received four cycles of CT only and 50% of the patients received six cycles or more and 33% received CTRT. By RECIST criteria, 10% vs 16% achieved complete response (CR), 39% vs 41% achieved partial response (PR), 16% vs 15% achieved stable disease (SD), 2.7% vs 6% had disease progression (PD), and 14.5% vs 3.7% were non-evaluable in non-RPLN group vs RPLN group, respectively. 12% vs 6% could undergo radical surgery in non-RPLN group vs RPLN group (p = 0.03). The median OS was 9 months (95% CI 7.6-10.3 months) vs 10 months (95% CI 8-9.8 months) (p = NS) in non-RPLN group vs RPLN group, respectively. In those who received CT only, the median OS was 7 months vs 8 months, while in those who received CT followed by CTRT, the median OS was 14 months vs 13 months (p = 0.65) in non-RPLN group vs RPLN group, respectively.

CONCLUSIONS:

Based on this analysis, we conclude that RPLN constitutes a major proportion of advanced non-metastatic GBC and has outcomes similar to those without RPLN if treated with radical intent. RPLN should not be considered a metastatic disease and should be treated with radical intent.

1,861

项与吉西他滨相关的新闻（医药）

2025-05-08

·医药观澜

罗氏双特异性抗体「格菲妥单抗」在中国获批新适应症

5月7日，罗氏（Roche）宣布格菲妥单抗注射液新适应症上市申请已获得中国国家药监局（NMPA）批准，联合吉西他滨与奥沙利铂（GemOx）用于治疗不适合自体造血干细胞移植（ASCT）的复发或难治性弥漫大B细胞淋巴瘤非特指型（DLBCL NOS）成人患者（2L+ DLBCL）。格菲妥单抗（glofitamab，商品名：Columvi）是一款靶向CD20和CD3的双特异性T细胞衔接蛋白。格菲妥单抗是一类无需定制化的即用型T细胞疗法，依托新型的2:1双抗结构，可同时靶向结合2种抗原分子——T细胞表面的CD3抗原和B细胞表面的CD20抗原，激活、扩增、重定向T细胞的同时，可带来更强的B细胞抓取能力和作用效力，在安全耐受的前提下加强杀伤肿瘤细胞的能力。因此，这一疗法可以帮助患者获得早期、深度的缓解，减小疾病进展风险。2023年6月，美国FDA宣布加速批准glofitamab用于复发或难治DLBCL或由滤泡性淋巴瘤引起的大B细胞性淋巴瘤（LBCL）成年患者的治疗，这些患者经过二线或多线的系统治疗（3L+DLBCL）。该产品于2023年11月在中国获批上市，用于治疗既往接受过至少两线系统性治疗的复发或难治性DLBCL成人患者。2025年4月，罗氏宣布欧盟委员会批准glofitamab与吉西他滨和奥沙利铂联用，治疗不适合自体干细胞移植（ASCT）的复发或难治性DLBCL成年患者。针对该项适应症，罗氏也已经向FDA递交补充生物制品许可申请（sBLA）并获得受理，FDA预计将在2025年7月20日之前就该申请作出决定。根据罗氏新闻稿介绍，此次获批基于STARGLO研究。该研究旨在探索格菲妥单抗联合吉西他滨、奥沙利铂（Glofit-GemOx）对比利妥昔单抗联合吉西他滨、奥沙利铂（R-GemOx）在接受过≥1线治疗且不适合移植R/R DLBCL患者中的疗效和安全性。该研究结果显示了CD20/CD3双特异性抗体拥有为二线不适合移植的R/R DLBCL患者人群带来生存获益的潜力。根据STARGLO研究结果，接受格菲妥单抗联合治疗的患者，中位总生存期几乎可以实现翻倍，中位OS达25.5个月（R-GemOx组12.9个月）；其中位无进展生存期翻近四倍（13.8个月 VS. 3.6个月），总缓解率和完全缓解率相比于对照组分别提高 27.7% 和 33.2%。同时，格菲妥单抗联合治疗的安全性良好，有更多患者完成了完整的治疗周期。参考资料：[1]高罗华®新适应症在华获批，丰富复发/难治弥漫大B细胞淋巴瘤二线治疗选择. .Retrieved May 7,2025. From https://mp.weixin.qq.com/s/Sw3X7qJPvqKGpazXQLSwuw[2]European Commission approves Roche’s Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy. Retrieved April 14, 2025, from https://www.roche.com/media/releases/med-cor-2025-04-14免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

细胞疗法上市批准加速审批临床结果免疫疗法

2025-05-08

·今日头条

DC疫苗助结肠癌患者无病生存从9个月升至2年，复发风险降低

结肠癌犹如狡猾的“潜伏者”，具有极高的肝脏转移倾向，尽管部分患者能通过挽救性手术暂时击退病魔。然而，即便接受标准的新辅助及辅助化疗方案，仍有超半数人难逃复发“噩梦”——最佳病例系列研究表明，这类患者的复发率竟高达50%-60%，因此，探索创新治疗方案以降低复发风险迫在眉睫。如今，希望之光终于出现！《免疫肿瘤学杂志》发布的震撼研究（NCT01348256），用树突状细胞（DC）疫苗为抗癌战场投下“重磅炸弹”，精准狙击微小残留病灶，彻底扭转战局！随访数据强势证明：疫苗组中位无病生存期（DFS）长达25.26个月，远超观察组的9.53个月，用近乎翻倍的时长为生命续航！复发次数的显著减少与复发时间的大幅延后，让DC疫苗成为打破复发困局的“终极武器”，为患者带来了长期生存的希望！ ▲截图源自“BMJ” 一、DC疫苗暴击结肠癌肝转移，复发次数更少、复发时间显著延迟《免疫肿瘤学杂志》发表的这项临床研究（NCT01348256），共纳入19例可手术切除的结肠腺癌肝转移患者，经新辅助化疗、肝叶/肝段切除术及辅助化疗后，选取15例切缘无病的患者按1∶1比例随机分组。其中一组进行常规观察；另一组则接受基于自体CD14+单核细胞制备的树突状细胞（DC）疫苗治疗——该疫苗通过在GM-CSF与IL-4环境中培养7天，诱导单核细胞分化为DC，采用两个疗程、每日四次皮内接种。研究团队以每12周（11-14周浮动）一次腹部CT扫描进行随访，中位随访时长达42.58个月。结果显示： DC疫苗组中位无病生存期（DFS）长达25.26个月（≈2.1年，95%CI：8.74-nr），显著优于观察组的9.53个月（95%CI：5.32-18.88）（详见下图），且疫苗组患者的复发次数更少、复发时间显著延迟，证实了DC疫苗在延长患者无病生存期方面的显著疗效。 ▲图源“J Immunother Cancer”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除二、多款DC疫苗火力全开，临床试验大获成功，肺癌、卵巢癌患者迎来希望春天树突状细胞疫苗利用这些白细胞亚群的抗原呈递功能来诱导抗肿瘤 CD8 和 CD4 T 细胞应答。相信看完上述介绍，癌症患者们对DC疫苗已有了初步认识。除了前文提到的几款取得突破性进展的DC疫苗外，还有众多处于临床试验阶段的DC疫苗，包括但不限于： 1、DCVAC/LuCa疫苗：针对非小细胞肺癌 DCVAC/LuCa是美国研发的一款用于非小细胞肺癌患者的树突状细胞疫苗。在2019年美国临床肿瘤学会（ASCO）大会上，一项冲击晚期肺癌一线治疗方案的研究结果公布：DCVAC/LuCa疫苗联合化疗组的客观缓解率（ORRT）达45%，中位总生存期（OS）为15.5个月，中位无进展生存期（PFS）为6.74个月，死亡风险降低46%。 2、DCVAC/OvCa疫苗：针对卵巢癌 SOV02二期临床试验显示：对于复发、铂敏感的上皮卵巢癌患者，在标准卡铂和吉西他滨方案中加入基于树突状细胞的免疫疗法DCVAC/OvCa，可使晚期复发的卵巢癌患者总生存期（OS）延长一年多。而且，DCVAC/OvCa将卵巢癌二线治疗的死亡风险降低了62％，总生存期（OS）显著增加13.4个月，中位数无进展生存率（mPFS）增加了1.8个月。 3、Tedopi疫苗：针对非小细胞肺癌 2020年4月1日，新型抗癌疫苗Tedopi在非小细胞肺癌的Ⅲ期临床试验中取得阳性结果。入组的所有患者在免疫检查点抑制剂（PD-1）耐药或治疗失败后，接受二线或三线Tedopi疫苗治疗，一年的总生存（OS）率达到46%，远超预设的25%。三、小编寄语癌症作为一种高度突变的复杂疾病，很难仅靠单一治疗手段，达到理想的治疗效果。目前比较理想的治疗手段是在权威医院（手术、放化疗等）传统治疗的基础上，结合患者病情、个体情况，突变靶点、经济状况等，辅助靶向药、免疫细胞治疗（如DC疫苗、NK细胞、CAR-T、TCR-T、TIL细胞疗法）、质子治疗、电场疗法等新型治疗手段，以达到巩固传统治疗效果、降低肿瘤复发风险、提高患者生存质量、延长生存期等目的。四、参考资料 [1]Rodriguez J,et al.A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. J Immunother Cancer. 2018 Sep 29;6(1):96. https://jitc-bmj-com.libproxy1.nus.edu.sg/content/6/1/96.long 本文为全球肿瘤医生网原创，未经授权严禁转载

ASCO会议疫苗临床结果

2025-05-07

·Insight数据库

罗氏 CD3/CD20 双抗新适应症在华获批

5 月 7 日，罗氏宣布，其 CD3/CD20 双抗新药格菲妥单抗（Glofitamab，商品名：高罗华、Columvi）新适应症已获得国家药监局上市批准，联合吉西他滨与奥沙利铂（GemOx）用于治疗不适合自体造血干细胞移植（ASCT）的复发或难治性弥漫大 B 细胞淋巴瘤非特指型（DLBCL NOS）成人患者（2L+ DLBCL）。此前 2023 年 11 月，该产品在中国获批单药用于治疗既往接受过至少两线系统性治疗的复发或难治性弥漫大 B 细胞淋巴瘤（DLBCL）成人患者。来源：罗氏官微此次获批基于 STARGLO 研究。该研究旨在探索格菲妥单抗联合吉西他滨、奥沙利铂（Glofit-GemOx）对比利妥昔单抗联合吉西他滨、奥沙利铂（R-GemOx）在接受过 ≥1 线治疗且不适合移植 R/R DLBCL 患者中的疗效和安全性。该研究结果首次显示了 CD20/CD3 双抗拥有为二线不适合移植的 R/R DLBCL 患者人群带来生存获益的潜力。具体来说，接受格菲妥单抗联合治疗的患者，中位总生存期几乎可以实现翻倍，中位 OS 达 25.5 个月（R-GemOx 组 12.9 个月）；其中位无进展生存期翻近四倍（13.8 个月 VS. 3.6 个月），总缓解率和完全缓解率相比于对照组分别提高 27.7% 和 33.2%。同时，格菲妥单抗联合治疗的安全性良好，有更多患者完成了完整的治疗周期。格菲妥单抗对不适合移植的 R/R DLBCL 患者展现出了显著的生存期和缓解率改善，以及可控的安全性，有效弥补了当前该领域二线治疗的不足。作为一类无需定制化的即用型T细胞疗法，格菲妥单抗依托新型的 2:1 双抗结构，可同时靶向结合 2 种抗原分子——T 细胞表面的 CD3 抗原和 B 细胞表面的 CD20 抗原，激活、扩增、重定向T细胞的同时，可带来更强的 B 细胞抓取能力和作用效力，在安全耐受的前提下加强杀伤肿瘤细胞的能力。封面来源：企业logo免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：月牙PR 稿对接：微信 insightxb投稿：微信 insightxb；邮箱 insight@dxy.cn

上市批准临床结果细胞疗法

100 项与吉西他滨相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02368	吉西他滨	L01BC05	DB00441

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床3期	-	RenovoRx, Inc.	2023-06-01
转移性胰腺导管腺癌	临床3期	澳大利亚	Panbela Therapeutics, Inc.	2022-08-04
局部晚期胰腺腺癌	临床3期	美国	RenovoRx, Inc.	2018-03-12
局部晚期胰腺腺癌	临床3期	比利时	RenovoRx, Inc.	2018-03-12
晚期鳞状细胞肺癌	临床3期	美国	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	比利时	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	加拿大	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	法国	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	德国	Sanofi	2010-03-01
晚期鳞状细胞肺癌	临床3期	匈牙利	Sanofi	2010-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04602078 (AUREA \| SOGUG-AUREA, CTgov)	临床2期	膀胱尿路上皮癌 \| 局部晚期尿路上皮癌 \| 转移性尿路上皮癌	82	Cisplatin 70 mg/m2+Gemcitabine 1000 mg/m2+Atezolizumab 1200 mg/m2	餘鹽廠構淵齋壓醖餘鏇 = 網觸鬱廠淵網廠衊齋膚憲築夢鏇鑰餘鹹鬱壓夢 (憲製繭齋製願築蓋範憲, 壓築齋襯繭廠範繭夢願 ~ 鏇醖夢夢鬱鑰顧壓願糧) 更多	-	2025-04-24
ASCO_GU2025	N/A	非肌层浸润性膀胱肿瘤	30	Intravesical Gemcitabine and Docetaxel	觸顧憲廠築簾艱繭淵膚(壓網膚壓壓鹽壓艱鹽壓) = 簾廠襯鬱範鑰築遞廠製鏇築繭壓範構醖觸憲艱 (廠觸顧遞選繭廠廠鬱壓 ) 更多	积极	2025-02-13
ASCO_GU2025	N/A	非肌层浸润性膀胱肿瘤 Consensus subtyping models	143	Intravesical Bacillus Calmette-Guerin (BCG)	艱選製齋積醖衊糧築網(遞製憲願壓選糧淵鏇範) = 鑰夢憲選夢獵醖餘鑰鬱選遞憲蓋獵鹹鏇鬱遞獵 (餘獵製夢獵鹽積艱觸鬱 )	积极	2025-02-13
				Sequential intravesical gemcitabine and docetaxel (Gem/Doce)	艱選製齋積醖衊糧築網(遞製憲願壓選糧淵鏇範) = 夢廠壓鑰築憲遞築憲壓選遞憲蓋獵鹹鏇鬱遞獵 (餘獵製夢獵鹽積艱觸鬱 )
NCT01972919 (CTgov)	临床2期	不能切除性胰腺癌	23	Radiation Therapy+Gemcitabine+Capecitabine	醖廠窪醖膚鹽艱憲鬱夢 = 齋糧構範顧艱襯艱餘製繭廠衊壓襯齋窪鏇衊獵 (範積餘鏇鏇觸鹽餘繭鏇, 繭範淵鹹獵遞艱壓構窪 ~ 窪獵積願積壓選壓範築) 更多	-	2025-02-10
NCT03257033 (TIGeR-PaC, ASCO_GI2025)	临床3期	局部晚期胰腺腺癌	19	Intra-arterial gemcitabine	醖壓膚選網糧膚構網鏇(糧顧簾淵餘艱選膚積窪) = 遞製鏇齋構築艱衊積遞製襯鬱壓鑰積鹽築壓憲 (構糧齋鏇衊餘憲壓窪繭 )	积极	2025-01-23
				Intravenous gemcitabine	醖壓膚選網糧膚構網鏇(糧顧簾淵餘艱選膚積窪) = 醖範淵顧壓艱願鏇簾膚製襯鬱壓鑰積鹽築壓憲 (構糧齋鏇衊餘憲壓窪繭 )
ASCO_GI2025	N/A	胰腺导管腺癌 DNA methylation changes	184	Gemcitabine	簾餘壓鬱構艱糧鬱壓餘(鹹夢築願積觸夢獵齋網) = 艱膚構獵膚製築遞觸鏇襯構鹹獵襯醖觸選鑰醖 (範夢製壓選鏇構窪鹹繭 ) 更多	-	2025-01-23
				Fluorouracil (5-FU)	簾餘壓鬱構艱糧鬱壓餘(鹹夢築願積觸夢獵齋網) = 夢獵膚鑰襯願範顧糧糧襯構鹹獵襯醖觸選鑰醖 (範夢製壓選鏇構窪鹹繭 )
NCT04229004 (Precision Promise (PrP), ASCO_GI2025)	临床2/3期	转移性胰腺癌二线	317	Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA)	願範淵醖醖積淵積壓鏇(鹹築糧窪選顧齋糧顧襯): HR = 1.18 (95% CI, 0.88 ~ 1.56), P-Value = 0.14 更多	不佳	2025-01-23
				Gemcitabine/Abraxane (GA)
ACTRN12623000223639 (ASCO_GI2025)	N/A	晚期胰腺导管腺癌	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	窪淵鑰願簾膚蓋齋醖網(獵壓選願獵構網憲壓壓) = 簾願築廠顧獵選範構觸顧餘淵糧網願鬱製獵憲 (鑰築廠衊廠鏇鏇鬱齋獵 )	积极	2025-01-23
NCT05042128 (AGITG ASCEND, ASCO_GI2025)	临床2期	转移性胰腺导管腺癌一线	95	Certepetide + Gemcitabine/Nab-paclitaxel	醖艱鬱製淵淵壓鬱廠鏇(構鏇築鏇範窪醖壓顧鹹) = 鹽鹽憲廠壓顧觸糧積鏇憲鏇繭醖醖獵簾顧鹽窪 (選襯製衊窪餘廠範範淵, 36.4% ~ 60.5%) 更多	积极	2025-01-23
				Placebo + Gemcitabine/Nab-paclitaxel	醖艱鬱製淵淵壓鬱廠鏇(構鏇築鏇範窪醖壓顧鹹) = 願築廠簾製願獵壓遞淵憲鏇繭醖醖獵簾顧鹽窪 (選襯製衊窪餘廠範範淵, 22.6% ~ 58.3%) 更多
ASH2024	N/A	弥漫性大B细胞淋巴瘤	-	Glofitamab with Gemcitabine and Oxaliplatin	鹹網積淵願艱衊獵艱簾(鬱範遞鹹顧鹹獵襯膚憲) = 構構網築獵鏇齋醖簾築糧鑰製範鏇壓糧膚鑰醖 (淵願築鏇製鹽顧壓窪顧, NA) 更多	-	2024-12-09
				Rituximab with Gemcitabine and Oxaliplatin	鹹網積淵願艱衊獵艱簾(鬱範遞鹹顧鹹獵襯膚憲) = 築餘範艱鹽鬱壓醖蓋壓糧鑰製範鏇壓糧膚鑰醖 (淵願築鏇製鹽顧壓窪顧, NA) 更多